Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

NCT05789043 PHASE3 RECRUITING

It is a RCT aimed to evaluate the Progression Free Survival of Camrelizumab combined with apatinib and temozolomide as First Line Therapy in Advanced Acral Melanoma.

Details

Lead sponsor	Peking University Cancer Hospital & Institute
Phase	PHASE3
Status	RECRUITING
Enrolment	140
Start date	Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Feb 15 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Acral Melanoma

Interventions

• camrelizumab+apatinib+TMZ
• camrelizumab+apatinib
• camrelizumab

Countries

China